Veerhealth Care Ltd (NIYATILEAS)
🎯 Key Takeaways
- Veerhealth Care Ltd appears to be in a high-growth, early-stage phase with significant volatility in financial performance and minimal institutional ownership. The company has shown sharp revenue expansion from ₹4 crore in FY25 to ₹25 crore in Q1FY27, but profitability remains erratic with frequent swings between operating profit and loss.
- Revenue grew 48.7% QoQ to ₹25 in Q1FY27.
- ⚠️ 1) High volatility in profitability despite revenue growth, with recurring net losses in recent quarters. 2) Lack of institutional ownership and low p
📖 The Story
Veerhealth Care Ltd appears to be in a high-growth, early-stage phase with significant volatility in financial performance and minimal institutional ownership. The company has shown sharp revenue expansion from ₹4 crore in FY25 to ₹25 crore in Q1FY27, but profitability remains erratic with frequent swings between operating profit and loss. Despite a high P/E of 66.7 and ROE of 6.9%, the company maintains a conservative balance sheet with negligible debt and positive cash flows from financing activities.
📰 What's Happening
Management has consistently highlighted expansion in manufacturing capacity and product diversification as key growth drivers, particularly through regulatory approvals and new product launches. The company secured multiple domestic and export orders in Q1FY27, contributing to a sixfold revenue increase YoY. Management also emphasized strengthening supply chain partnerships and investing in formulation capabilities to support long-term scalability. No major M&A or leadership changes were reported in recent filings.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 4 | 4 | 7 | 17 | 25 |
| Operating Profit | -0 | 0 | 1 | 0 | 2 |
| OPM % | -7.1% | 5.5% | 12.1% | 2.3% | 6.2% |
| Net Profit | 0 | 0 | 0 | -0 | 1 |
| EPS | ₹0.12 | ₹0.13 | ₹0.20 | ₹-0.18 | ₹0.61 |
Revenue has grown exponentially from ₹4 crore in Q2FY25 to ₹25 crore in Q1FY27, reflecting successful market penetration and order execution. However, operating margins remain highly volatile, swinging from -7.1% in Q2FY25 to 12.1% in Dec 2025, indicating operational instability despite scale. Profitability has not translated into consistent net income, with net losses recurring in Mar 2026 and Sep 2025, suggesting cost pressures or ramp-up inefficiencies during expansion.
🔮 Management Outlook & What's Next
Management has expressed confidence in sustaining double-digit growth over the next 2-3 years, driven by new product approvals and expansion into regulated markets. They have indicated plans to scale up production while maintaining quality compliance, though no formal revenue or margin guidance was provided in the latest filing. The focus remains on capitalizing on first-mover advantages in niche therapeutic segments without committing to specific financial targets.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 20 | 20 | 20 | 20 |
| Reserves | 2 | 2 | 3 | 3 |
| Borrowings | 0 | 5 | 5 | 5 |
| Total Liabilities | 31 | 34 | 34 | 44 |
| Fixed Assets | 15 | 20 | 23 | 23 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 31 | 34 | 34 | 44 |
The balance sheet remains stable with no increase in borrowings over the past three years, indicating self-funded growth through retained cash flows and equity reserves. Equity remains flat at ₹20 crore, while reserves have modestly increased, suggesting limited reinvestment of profits. Total assets have grown from ₹34 crore to ₹44 crore, primarily due to operational expansion, but the capital structure remains lean with minimal leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -0 |
| Investing | -8 |
| Financing | +10 |
| Net Cash Flow | +1 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 31.5% | 31.5% | 31.5% | 31.9% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 57.0% | 55.1% | 54.3% | 54.0% |
| # Shareholders | 10,846 | 10,455 | 10,027 | 9,315 |
Promoter holding has slightly declined from 31.91% to 31.5% over the last four quarters, with no FII or DII holdings reported, indicating limited institutional interest. The number of public shareholders has increased steadily, suggesting retail investor participation but fragmented ownership. No pledging of shares was disclosed, and there has been no significant stake sale or acquisition by promoters.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.64 L Cr | 38.4 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.45 L Cr | 83.8 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.90 L Cr | 79.8 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.15 L Cr | 25.7 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.14 L Cr | 33.9 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.01 L Cr | 92.0 | 20.8% | 20.6% | 0.45 |
| LUPIN | 98,424 | 17.4 | 27.9% | 24.7% | 0.26 |
| MANKIND | 98,293 | 48.1 | 13.9% | 12.7% | 0.38 |
| DRREDDY | 96,906 | 30.0 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 95,300 | 25.9 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) High volatility in profitability despite revenue growth, with recurring net losses in recent quarters. 2) Lack of institutional ownership and low public float may lead to high volatility and limited liquidity. 3) Dependence on regulatory approvals and niche product demand exposes the company to execution and compliance risks. 4) Rising operational expenses during expansion could pressure cash flows if revenue growth slows.
📋 Recent Filings
-
🔴 annual report 31 August 2026Veerhealth Care Limited's 2025-26 Annual Report shows revenue growth to [amount context mismatch] Lakhs from ₹1667.05 Lakhs, with net profit rising to...
-
🟡 Board Meeting 31 August 2026The 34th AGM of Veerhealth Care Limited (BSE: NIYATILEAS) scheduled for September 23, 2026, will focus on director reappointments, auditor confirmatio...
-
🔴 annual report 31 August 2026Veerhealth Care Limited announced its 34th Annual General Meeting scheduled for 23 September 2026 via video conference, reminding shareholders to upda...
-
🟡 concall transcript 31 March 2024Veerhealth Care reported FY24 revenue of INR1,461.29 lakhs with EBITDA margin at 13.70%, driven by 30% export contribution and 55% contract manufactur...
🧠 Analyst's Read
Veerhealth Care is executing a high-risk, high-reward expansion strategy with strong top-line momentum but inconsistent profitability. Investors should monitor quarterly margin trends and the commercial traction of newly launched products to assess sustainability of growth. The absence of institutional backing and volatile earnings require careful scrutiny of management's ability to scale efficiently.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-03.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when NIYATILEAS files new disclosures
Track NIYATILEAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track NIYATILEAS — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd